Market Movers

Molina Healthcare, Inc. (MOH)

296.59 USD +4.81 (+1.65%) Volume: 0.88M

With a robust trading session, Molina Healthcare, Inc.’s stock price stands at 296.59 USD, marking a noteworthy +1.65% rise, backed by a solid trading volume of 0.88M. Despite a YTD percentage change of -18.22%, the healthcare giant continues to be a focal point in the stock market.

Latest developments on Molina Healthcare, Inc.

Molina Healthcare has been making significant moves in the healthcare industry recently, with the company securing major contracts to serve dual eligible populations in Michigan and Idaho through 2026. This expansion of services has caught the attention of analysts, with JPMorgan seeing Molina Healthcare stock as fairly valued entering 2025. Despite receiving a neutral rating from JPMorgan Chase & Co., experts remain optimistic about the company’s strong fundamentals. In addition, Molina Healthcare is set to host a seasonal depression awareness event in Laredo, showcasing their commitment to community health initiatives. These developments have contributed to the excitement surrounding Molina Healthcare‘s stock price movements today.

Molina Healthcare, Inc. on Smartkarma

Analysts on Smartkarma, such as Baptista Research, have been covering Molina Healthcare closely. In a recent report titled “Molina Healthcare Inc.: These Are The 6 Biggest Factors Impacting Its Performance In 2025 & Beyond! – Major Drivers,” Baptista Research highlighted the company’s mixed performance in the third quarter of 2024. Despite facing challenges such as upward pressure on medical costs, Molina Healthcare reported adjusted earnings per share of $6.01 on $9.7 billion of premium revenue. The company maintained a robust adjusted pre-tax margin of 4.5%, showcasing a balanced business portfolio.

A look at Molina Healthcare, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Molina Healthcare has a positive long-term outlook. With high scores in Growth and Resilience, the company is poised for continued expansion and stability in the future. This indicates that Molina Healthcare is well-positioned to grow its business and navigate challenges effectively.

Despite a lower score in Dividend, Molina Healthcare‘s overall outlook remains strong. The company’s focus on providing healthcare services to low-income families and individuals, combined with its presence in multiple states, showcases its commitment to serving its community. With a solid foundation in place, Molina Healthcare is likely to maintain its momentum and drive success in the managed care industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

LKQ Corporation (LKQ)

36.99 USD +0.38 (+1.04%) Volume: 3.66M

Explore LKQ Corporation’s stock price performance, trading at 36.99 USD, witnessing an upswing this session by +1.04%, backed by a trading volume of 3.66M. Despite the positive momentum, the stock has observed a YTD decrease of -22.14%, reflecting its volatile journey in the market.

Latest developments on LKQ Corporation

LKQ Corp, a top pick in the automotive aftermarket sector according to Jefferies, saw its stock price fall on Tuesday, underperforming the market. Despite this, LKQ’s stock price managed to rise by 1.1%. However, concerns have been raised about the company’s declining stock performance despite decent financials. Retirement Systems of Alabama recently sold shares in LKQ Co., further impacting the stock price. This follows a previous fall in stock price on Monday, where LKQ underperformed the market once again, with a 0.1% decrease. Despite these fluctuations, LKQ’s stock price managed to trade 0.5% higher, reflecting the ongoing volatility in the market.

LKQ Corporation on Smartkarma

Analysts at Baptista Research have been closely monitoring Lkq Corp on Smartkarma, providing insightful coverage on the company’s performance and future outlook. In their research reports, such as “LKQ Corporation: What Is The Expected Impact Of Revenue Diversification & Margin Improvement Strategies? – Major Drivers,” they delve into the challenges and strategic maneuvers impacting Lkq Corp‘s market position. With a bullish sentiment, Baptista Research evaluates factors influencing the company’s price and conducts independent valuations using a Discounted Cash Flow methodology.

Furthermore, Baptista Research‘s analysis on Lkq Corp‘s focus on niche markets with high margin potential and adoption of digital and technological solutions, as seen in reports like “LKQ Corporation: Adoption and Expansion of Digital and Technological Solutions! – Major Drivers,” highlights the complexities and opportunities facing the company. Despite economic pressures and operational headwinds, Lkq Corp‘s strategic growth initiatives and commitment to operational excellence set a clear path for future developments, as outlined by Baptista Research‘s thorough evaluations.

A look at LKQ Corporation Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Lkq Corp has a positive long-term outlook. With high scores in value, dividend, and momentum, the company is positioned well for future growth and stability. Lkq Corp‘s focus on providing automotive products and services, along with its strong performance in terms of resilience and growth, further solidifies its position in the market.

Lkq Corp‘s impressive scores across various factors indicate a promising future for the company. With a strong emphasis on value and dividend, as well as a solid momentum score, Lkq Corp is poised for continued success in the automotive industry. Additionally, the company’s resilience and growth scores suggest that it is well-equipped to navigate challenges and capitalize on opportunities in the long run.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Centene Corporation (CNC)

59.49 USD +1.68 (+2.91%) Volume: 5.81M

Centene Corporation’s stock price stands at 59.49 USD, marking an impressive trading session increase of +2.91%. Despite a year-to-date decrease of -19.75%, the robust trading volume of 5.81M showcases the stock’s potential. Explore CNC’s dynamic performance and investment opportunities.

Latest developments on Centene Corporation

Recent insider buying activities at Centene Corp (CNC) have caught the attention of investors, with directors like Christopher Coughlin and Theodore Samuels purchasing significant amounts of company stock. Despite underperforming compared to competitors on Tuesday, the stock managed to outperform them on other days, showing resilience in the face of losses. With notable acquisitions by MML Investors Services LLC and Sanctuary Advisors LLC, it seems that confidence in Centene remains strong. Analysts at JPMorgan Chase & Co. have reaffirmed an overweight rating, while Jefferies expresses concerns with an underperform rating. Director Dallas H. James and Jessica Blume also joined in on the buying spree, indicating a positive outlook for Centene Corp‘s stock price movement.

Centene Corporation on Smartkarma

Analysts on Smartkarma, like Baptista Research, are optimistic about Centene Corp. According to Baptista Research‘s report, titled “Centene Corporation: Operational Efficiency & AI Utilization Driving Our Optimism! – Major Drivers,” the company’s third-quarter financial results for 2024 exceeded expectations. Centene Corporation achieved an adjusted diluted EPS of $1.62, attributing the outperformance to realized tax benefits and accelerated income tax benefits. The report highlights the company’s nuanced performance, showcasing strengths and ongoing challenges within its operations.

A look at Centene Corporation Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Centene Corporation, a multi-line managed care organization, is poised for a strong long-term outlook based on its Smartkarma Smart Scores. With top scores in Value and Growth, the company demonstrates solid fundamentals and potential for expansion. While its Dividend score is lower, Centene’s focus on providing Medicaid and Medicaid-related programs, along with specialty services like behavioral health, positions it well for future growth and success.

Although Centene Corp‘s Resilience and Momentum scores are moderate, its high scores in Value and Growth indicate a promising outlook. The company’s presence in multiple states and diverse range of health plans highlight its strong foundation in the healthcare industry. With a focus on innovation and providing essential healthcare services, Centene Corp is well-positioned to navigate challenges and capitalize on opportunities in the evolving healthcare landscape.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

CVS Health Corporation (CVS)

45.28 USD +1.24 (+2.82%) Volume: 23.76M

CVS Health Corporation’s stock price sees a promising rise of +2.82% this trading session, reaching $45.28 with a robust trading volume of 23.76M, despite a challenging year-to-date percentage change of -42.65%.

Latest developments on CVS Health Corporation

CVS Health Corporation has been facing a tumultuous time in the stock market recently, with shares falling a further 17% in the past week alone. The healthcare giant has been hit from all sides, with challenges in its insurance business persisting and accusations of filling illegal opioid prescriptions. President Trump’s comments about ‘knocking out’ drug industry middlemen have also had a negative impact on CVS, UnitedHealth, and Cigna stock prices. The company’s stock is currently at its worst month in decades, with the Justice Department even suing CVS for alleged violations. Despite these challenges, CVS Health remains resilient, announcing pricing of maximum tender offers and debt tender offers amidst the stock price turmoil.

CVS Health Corporation on Smartkarma

Analysts at Baptista Research on Smartkarma have provided insightful coverage of Cvs Health Corp, highlighting key drivers of growth and strategic initiatives. In their report titled “CVS Health Corporation: Expansion & Optimization of Health Services As A Critical Factor Driving Growth! – Major Drivers,” they discuss the company’s third-quarter 2024 earnings report, noting a 6% increase in revenue to approximately $95.4 billion. However, challenges in the Health Care Benefits segment were indicated by the adjusted earnings per share of $1.09. The analysts’ bullish sentiment suggests optimism for CVS Health’s future prospects.

Furthermore, Baptista Research‘s analysis in the report “CVS Health Corporation: Strategic Leverage in Pharmacy Benefit Management (PBM) and Insurance Operations! – Major Drivers” delves into the company’s performance in the second quarter of 2024. They highlight mixed financial results, with adjusted earnings per share of $1.83 and revenues exceeding $91 billion. Operating cash flow of $8 billion for the first half of the year was supported by strong performances in the Health Services and Pharmacy & Consumer Wellness segments. This positive assessment underscores the potential strategic leverage CVS Health holds in its key operations.

A look at CVS Health Corporation Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, CVS Health Corp seems to have a positive long-term outlook. With high scores in both the value and dividend categories, the company appears to be a strong investment option for those looking for stability and potential returns. While the growth, resilience, and momentum scores are not as high, the overall outlook for CVS Health Corp remains promising.

As an integrated pharmacy health care provider, CVS Health Corporation offers a wide range of services including pharmacy benefit management, mail order, retail and specialty pharmacy, disease management programs, and retail clinics. With a strong presence in the U.S., the District of Columbia, and Puerto Rico, CVS Health Corp is well-positioned to continue providing essential healthcare services to communities across the country.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Cboe Global Markets, Inc. (CBOE)

200.07 USD +1.99 (+1.00%) Volume: 1.14M

Discover Cboe Global Markets, Inc.’s stock price performance, currently standing at 200.07 USD, marking a positive trading session with a 1.00% increase. With a robust trading volume of 1.14M, CBOE has shown a promising year-to-date percentage change of +12.05%, indicating a strong market presence and growth potential.

Latest developments on Cboe Global Markets, Inc.

Today, Cboe Global Markets Inc. stock is outperforming its competitors following a strong trading day. The company’s new vision is reflected in Cboe Data Vantage, showing proactive strategies in index options trading which continues to see growth as investors seek broader market exposure. Despite this positive momentum, EVP Adam Inzirillo recently sold $5,010 in stock. On Monday, Cboe Global Markets Inc. stock underperformed compared to competitors like Coinbase, which has ranked fifth globally in exchange revenue, surpassing Nasdaq and CBOE.

A look at Cboe Global Markets, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Looking at the Smartkarma Smart Scores for Cboe Global Markets, the company’s long-term outlook appears to be positive. With a high score in Growth and Resilience, Cboe Global Markets shows potential for continued expansion and stability in the market. This indicates that the company is well-positioned to adapt to changing market conditions and sustain its growth over time.

While Cboe Global Markets may not score as high in Value and Dividend, its strong performance in Growth and Resilience suggests that investors may still find value in the company’s stock. With a solid momentum score as well, Cboe Global Markets seems to have the potential to maintain its upward trajectory in the future. Overall, the company’s Smart Scores paint a promising picture for its long-term prospects in the marketplace.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

McKesson Corporation (MCK)

570.98 USD +8.20 (+1.46%) Volume: 1.13M

McKesson Corporation’s stock price soared to 570.98 USD, marking a positive shift of +1.46% in the latest trading session with a volume of 1.13M. This robust performance reflects an impressive YTD increase of +23.79%, highlighting MCK’s potent investment potential.

Latest developments on McKesson Corporation

McKesson Corp. stock experienced underperformance on Monday in comparison to its competitors. However, recent analyses from the Zacks Analyst Blog have highlighted McKesson alongside Doximity and Veracyte as promising investments. Additionally, financial experts like Gordon Reid have recommended adding McKesson stock to portfolios, citing its potential for growth. Recent moves in the market, such as B. Riley Wealth Advisors Inc. selling McKesson shares and Morgan Stanley raising the price target to $642.00, have also impacted the stock price movements today.

McKesson Corporation on Smartkarma

Analysts on Smartkarma, such as Baptista Research, have been closely covering Mckesson Corp and providing bullish insights on the company’s performance. In one report titled “McKesson Corporation: Will Its Cost Optimization & Operational Efficiencies Help Alter The Playing Field? – Major Drivers”, the analysts highlighted the company’s second quarter fiscal 2025 results, showing a robust 21% year-over-year revenue increase driven by the U.S. Pharmaceutical segment. Another report titled “McKesson Corporation: Expanding Oncology & Specialty Pharmaceutical Services As Well As Distribution & Sourcing! – Major Drivers” discussed the company’s first quarter fiscal 2025 earnings, which exceeded expectations with a 6% revenue increase and an adjusted earnings per share increase of 8%.

A look at McKesson Corporation Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

McKesson Corp, a company that distributes pharmaceuticals and medical supplies, has received high scores in Growth, Resilience, and Momentum according to Smartkarma Smart Scores. This indicates a positive long-term outlook for the company, suggesting strong potential for growth and the ability to weather economic challenges. With a focus on developing software and providing solutions for the healthcare industry, McKesson Corp is positioned well for continued success in the future.

While the company may not score as high in terms of value and dividend payouts, its strong performance in Growth, Resilience, and Momentum bodes well for investors looking for a company with long-term sustainability and potential for growth. McKesson Corp’s focus on data integration and healthcare solutions further solidifies its position as a key player in the industry, making it a company to watch for those interested in investing in the healthcare sector.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

The Cigna Group (CI)

282.41 USD +16.82 (+6.33%) Volume: 4.83M

The Cigna Group’s stock price soared to 282.41 USD, marking a significant trading session increase of +6.33%. Despite a YTD decrease of -5.69%, the robust trading volume of 4.83M underscores investor interest in CI’s resilient performance.

Latest developments on The Cigna Group

Today, Cigna Group stock prices are experiencing significant movements in response to President Trump’s recent comments about reforming the drug industry middlemen. Following Trump’s promise to ‘knock out’ these middlemen, shares of UnitedHealth, CVS, and Cigna have taken a hit. This statement has caused uncertainty in the healthcare sector, leading to a plunge in Humana and Cigna shares. Despite the market reaction, some analysts see this as a potential buying opportunity. The Cigna Group, listed on the NYSE as CI, has seen its shares both gap up and gap down in response to these developments. Overall, the health insurer’s stock is poised for growth amid challenges, making it a top socially responsible dividend stock with a 2.0% yield. As the industry navigates this period of volatility, investors are closely monitoring Cigna Group‘s performance.

The Cigna Group on Smartkarma

Analysts at Baptista Research on Smartkarma have published a bullish report on Cigna Group, highlighting the company’s specialty market position and biosimilars strategy as major drivers for their optimism. The third-quarter 2024 earnings for Cigna Group showed a net income of $739 million or $2.63 per share, despite being impacted by a significant non-cash after-tax net realized investment loss of $1 billion related to VillageMD. This loss resulted in a write-down of assets and an impairment charge, which has been excluded from adjusted operating income and earnings per share.

For more detailed insights, readers can refer to the research report titled “Cigna Corporation: Specialty Market Position & Biosimilars Strategy Driving Our Bullishness! – Major Drivers” by Baptista Research on Smartkarma. The report provides a comprehensive analysis of Cigna Group‘s financial performance and strategic initiatives, offering valuable information for investors looking to understand the company’s current position and future prospects. The analysts’ bullish sentiment reflects confidence in Cigna Group‘s growth potential and strategic direction in the healthcare industry.

A look at The Cigna Group Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on Smartkarma Smart Scores, Cigna Group seems to have a positive long-term outlook. With high scores in Dividend and Value, the company appears to be financially stable and capable of providing good returns to investors. However, its Growth, Resilience, and Momentum scores are slightly lower, indicating some room for improvement in terms of expansion, adaptability, and market performance. Overall, Cigna Group‘s strong foundation and consistent dividend payouts could make it an attractive option for those seeking a reliable investment in the insurance sector.

The Cigna Group, operating as an insurance company, offers a variety of insurance products and services to individuals, families, and businesses globally. With a focus on life, accident, disability, supplemental, medicare, and dental insurance, the company plays a crucial role in providing financial protection and security to its customers. By maintaining high scores in Dividend and Value, Cigna Group demonstrates its commitment to financial stability and shareholder returns, making it a potentially lucrative option for long-term investors looking for a reliable insurance provider.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Jabil Inc. (JBL)

143.69 USD +9.73 (+7.26%) Volume: 4.73M

Jabil Inc.’s stock price soars to 143.69 USD, marking a significant trading session increase of +7.26%. With a robust trading volume of 4.73M and an impressive year-to-date percentage change of +12.79%, JBL’s stock performance continues to attract investors.

Latest developments on Jabil Inc.

Jabil Circuit stock soared today after the company reported strong Q1 earnings, beating estimates by $0.12 and surpassing revenue expectations. The company cited increased demand in data infrastructure as a key driver for its success. Jabil also raised its revenue outlook for FY2025 to $27.3 billion, fueled by growth in cloud services. This positive news led to a surge in stock price, with investors reacting favorably to the company’s performance. With Jabil’s focus on data centers and cloud services, the outlook remains optimistic for the company’s future earnings and growth potential.

Jabil Inc. on Smartkarma

Analysts at Baptista Research are optimistic about Jabil Circuit‘s future, especially with its diversification into high-margin AI business. In their recent report titled “Jabil Inc.: Will The Diversification Into High-Margin AI Business Yield Dividends? – Major Drivers”, they highlighted the company’s strategic achievements and organizational changes. Baptista Research aims to evaluate the various factors that could impact Jabil’s stock price in the near future and has conducted an independent valuation using a Discounted Cash Flow (DCF) methodology.

Another report by Baptista Research, titled “Jabil Inc.: How Much Will Their Revenues Grow Given The Focus On AI & Data Center Markets? – Major Drivers”, discussed Jabil’s strong financial performance in the third quarter of fiscal year 2024. With revenues exceeding expectations by $265 million and significant contributions from connected devices and networking sectors, Jabil seems well-positioned for growth. The analysts are bullish on Jabil’s prospects in the AI and data center markets, emphasizing the company’s adaptability to changing market dynamics.

A look at Jabil Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Jabil Circuit shows a promising long-term outlook. With a high momentum score of 5, the company is experiencing strong positive price trends that indicate potential for future growth. Additionally, Jabil Circuit scores well in growth, with a score of 4, suggesting that the company has good prospects for expanding its business in the coming years. However, the company’s scores in other areas such as value, dividend, and resilience are more moderate, indicating room for improvement in these areas.

Jabil Circuit, Inc. is an electronic manufacturing services provider that caters to various electronics markets. The company offers a range of services including circuit design, board design, assembly, system assembly, repair, and warranty services. With its strong momentum and growth scores, Jabil Circuit appears to be on a positive trajectory for the future. However, areas such as value, dividend, and resilience could be areas of focus for the company to enhance its overall outlook and performance in the long term.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Biggest stock gainers today in S&P 500

Biggest stock losers today in S&P 500

What is Smartkarma SmartScore?

It is a compound score for a Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores (Value, Dividend, Growth, Resilience, Momentum scores) computed by Smartkarma.

The best stock screener – Smartkarma SmartScore Screener

Smartkarma’s stock screener, Smartkarma SmartScore Screener, allows you to easily discover undervalued gems, high dividend stocks, and high growth stocks, across multiple countries and sectors.

Explore the Smartkarma SmartScore Screener now.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

UnitedHealth Group Incorporated (UNH)

499.72 USD +14.20 (+2.92%) Volume: 10.0M

UnitedHealth Group Incorporated’s stock price surged to $499.72, marking a positive change of +2.92% this trading session with a trading volume of 10.0M, despite a year-to-date percentage change of -5.08%, showcasing its potential for investors in the healthcare sector.

Latest developments on UnitedHealth Group Incorporated

UnitedHealth Group has been facing a series of challenges recently, from a health data breach lawsuit in Nebraska to negative stock movements down 15.9% in the past three months. The company’s CEO, Andrew Witty, addressed backlash against the insurer, while the acquisition of OrthoAlliance showcased growing consolidation in the healthcare industry. Despite a $69 million settlement over low-performing retirement plans and attempts to stop the sale of Luigi Mangione merchandise, UnitedHealth’s stock price saw a 3% increase. However, concerns over Medicare for All and the company’s unchecked growth have also been highlighted, indicating potential trouble ahead. With ongoing controversies and legal battles, investors are closely monitoring UnitedHealth Group’s stock outlook amidst a volatile market.

UnitedHealth Group Incorporated on Smartkarma

Analyst Joe Jasper from Smartkarma has upgraded his coverage on UnitedHealth Group to Market Weight, citing new risk-off signals that suggest a pullback in the S&P 500 and QQQ. Jasper is looking for potential pullback zones between 5100-5191 on the S&P 500 and $443-$449 on the QQQ. He notes that the Russell 2000 small-caps and the Dow remain bullish, while the S&P 500 and Nasdaq 100 are experiencing a pullback/consolidation phase. Jasper expects the trend of small-cap outperformance to continue for months or longer, as the Russell 2000 vs. S&P 500 ratio reverses a 3.5-year downtrend.

A look at UnitedHealth Group Incorporated Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

UnitedHealth Group has received a positive overall outlook based on the Smartkarma Smart Scores. With a strong score of 4 for Dividend, investors can expect a reliable and consistent return on their investment. Additionally, the company scored well in Growth, Resilience, and Momentum, all with a score of 3, indicating a stable and growing business model. While the Value score is slightly lower at 3, UnitedHealth Group still presents a solid investment opportunity for those looking for long-term growth and stability in the healthcare sector.

UnitedHealth Group Incorporated, a company that owns and manages organized health systems, is positioned well for the future according to the Smartkarma Smart Scores. With a focus on providing employers with products and resources for employee benefit programs, UnitedHealth serves customers globally. The company’s strong scores across various factors such as Dividend, Growth, Resilience, and Momentum reflect its stability and potential for continued success in the healthcare industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma